Disruption of zinc neuromodulation by Aß oligomers: Therapeutic implications

Current Pharmaceutical Design

Volumn 20, Issue 15, 2014, Pages 2520-2524

  Vogler, Emily C ^a   Busciglio, Jorge ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Amyloid beta; Oligomers; Synapses; Zinc

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN OLIGOMER; N METHYL DEXTRO ASPARTIC ACID; OLIGOMER; UNCLASSIFIED DRUG; ZINC;

ALZHEIMER DISEASE; ARTICLE; BRAIN METABOLISM; EXCITOTOXICITY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HIPPOCAMPAL CA3 REGION; HOMEOSTASIS; HUMAN; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; SEIZURE; SPATIAL MEMORY; ANIMAL; DRUG EFFECTS; HIPPOCAMPUS; METABOLISM; PHYSIOLOGY; PROTEIN MULTIMERIZATION; SYNAPSE; SYNAPTIC TRANSMISSION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; HIPPOCAMPUS; HOMEOSTASIS; HUMANS; PROTEIN MULTIMERIZATION; SYNAPSES; SYNAPTIC TRANSMISSION; ZINC;

EID: 84903697696     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990510     Document Type: Article

References (82)

1. Lue LF, Kuo YM, Roher AE, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 1999; 155: 853-62.
2. Naslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA: the J Am Med Assoc 2000; 283: 1571-7.
3. Lambert MP, Barlow AK, Chromy BA, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998; 95: 6448-53.
4. Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416: 535-9.
5. Lesne S, Koh MT, Kotilinek L, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006; 440: 352-7.
6. Deshpande A, Kawai H, Metherate R, Glabe CG, Busciglio J. A role for synaptic zinc in activity-dependent Abeta oligomer formation and accumulation at excitatory synapses. J Neurosci 2009; 29: 4004-15.
7. Snyder EM, Nong Y, Almeida CG, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nature Neurosci 2005; 8: 1051-8.
8. Rammes G, Hasenjager A, Sroka-Saidi K, Deussing JM, Parsons CG. Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of beta-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices. Neuropharmacology 2011; 60: 982-90.
9. Balducci C, Tonini R, Zianni E, et al. Cognitive deficits associated with alteration of synaptic metaplasticity precede plaque deposition in AbetaPP23 transgenic mice. J Alzheimer's disease: JAD 2010; 21: 1367-81.
10. Palmiter RD, Cole TB, Quaife CJ, Findley SD. ZnT-3, a putative transporter of zinc into synaptic vesicles. Proc Natl Acad Sci USA 1996; 93: 14934-9.
11. Braak H, Braak E. Neuropathological stageing of Alzheimerrelated changes. Acta Neuropathologica 1991; 82: 239-59.
12. Suh SW, Jensen KB, Jensen MS, et al. Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains. Brain Res 2000; 852: 274-8.
13. Zhang CF, Yang P. Zinc-induced aggregation of Abeta (10-21) potentiates its action on voltage-gated potassium channel. Biochem Biophys Res Communicat 2006; 345: 43-9.
14. Garai K, Sahoo B, Kaushalya SK, Desai R, Maiti S. Zinc lowers amyloid-beta toxicity by selectively precipitating aggregation intermediates. Biochemistry 2007; 46: 10655-63.
15. Wang CY, Wang T, Zheng W, et al. Zinc overload enhances APP cleavage and Abeta deposition in the Alzheimer mouse brain. PloS one 2010; 5: e15349.
16. Zirah S, Kozin SA, Mazur AK, et al. Structural changes of region 1-16 of the Alzheimer disease amyloid beta-peptide upon zinc binding and in vitro aging. J Biological Chem 2006; 281: 2151-61.
17. Tsvetkov PO, Popov IA, Nikolaev EN, et al. Isomerization of the Asp7 residue results in zinc-induced oligomerization of Alzheimer's disease amyloid beta(1-16) peptide. Chembiochem: a Eur J Chem Biol 2008; 9: 1564-7.
18. Johnstone EM, Chaney MO, Norris FH, Pascual R, Little SP. Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis. Brain research. Molecular Brain Res 1991; 10: 299-305.
19. Bush AI, Pettingell WH, Multhaup G, et al. Rapid induction of Alzheimer A beta amyloid formation by zinc. Science 1994; 265: 1464-7.
20. Huang J, Yao Y, Lin J, et al. The solution structure of rat Abeta-(1-28) and its interaction with zinc ion: insights into the scarcity of amyloid deposition in aged rat brain. J Biol Inorg Chem 2004; 9: 627-35.
21. Talmard C, Leuma Yona R, Faller P. Mechanism of zinc(II)-promoted amyloid formation: zinc(II) binding facilitates the transition from the partially alpha-helical conformer to aggregates of amyloid beta protein(1-28). J Biol Inorg Chem 2009; 14: 449-55.
22. Tougu V, Karafin A, Palumaa P. Binding of zinc(II) and copper(II) to the full-length Alzheimer's amyloid-beta peptide. J Neurochem 2008; 104: 1249-59.
23. Noy D, Solomonov I, Sinkevich O, et al. Zinc-amyloid beta interactions on a millisecond time-scale stabilize non-fibrillar Alzheimer-related species. J Am Chem Soc 2008; 130: 1376-83.
24. Baum L, Chan IH, Cheung SK, et al. Serum zinc is decreased in Alzheimer's disease and serum arsenic correlates positively with cognitive ability. Biometals: an Int J Role Metal Ions Biol, Biochem, Med 2010; 23: 173-9.
25. Bush AI. Copper, zinc, and the metallobiology of Alzheimer disease. Alzheimer Disease Associated Disorders 2003; 17: 147-50.
26. Sensi SL, Rapposelli IG, Frazzini V, Mascetra N. Altered oxidantmediated intraneuronal zinc mobilization in a triple transgenic mouse model of Alzheimer's disease. Exp Gerontol 2008; 43: 488-92.
27. Adlard PA, Parncutt JM, Finkelstein DI, Bush AI. Cognitive loss in zinc transporter-3 knock-out mice: a phenocopy for the synaptic and memory deficits of Alzheimer's disease? J Neuroscience: the official J Soc Neurosci 2010; 30: 1631-6.
28. Valente T, Auladell C. Developmental expression of ZnT3 in mouse brain: correlation between the vesicular zinc transporter protein and chelatable vesicular zinc (CVZ) cells. Glial and neuronal CVZ cells interact. Mol Cell Neurosci 2002; 21: 189-204.
29. Shen H, Zhang Y, Xu J, et al. Zinc distribution and expression pattern of ZnT3 in mouse brain. Biol Trace Elem Res 2007; 119: 166-74.
30. Perez-Clausell J, Danscher G. Intravesicular localization of zinc in rat telencephalic boutons. A histochemical study. Brain Res 1985; 337: 91-8.
31. Acsady L, Kamondi A, Sik A, Freund T, Buzsaki G. GABAergic cells are the major postsynaptic targets of mossy fibers in the rat hippocampus. The J neuroscience: the official J Soc Neurosci 1998; 18: 3386-403.
32. Laube B, Kuhse J, Betz H. Kinetic and mutational analysis of Zn2+ modulation of recombinant human inhibitory glycine receptors. J Physiol 2000; 522 Pt 2: 215-30.
33. Miller PS, Da Silva HM, Smart TG. Molecular basis for zinc potentiation at strychnine-sensitive glycine receptors. J Biol Chem 2005; 280: 37877-84.
34. Zhang HX, Thio LL. Zinc enhances the inhibitory effects of strychnine-sensitive glycine receptors in mouse hippocampal neurons. J Neurophysiol 2007; 98: 3666-76.
35. Cohen-Kfir E, Lee W, Eskandari S, Nelson N. Zinc inhibition of gamma-aminobutyric acid transporter 4 (GAT4) reveals a link between excitatory and inhibitory neurotransmission. Proc Natl Acad Sci USA 2005; 102: 6154-9.
36. Ju P, Aubrey KR, Vandenberg RJ. Zn2+ inhibits glycine transport by glycine transporter subtype 1b. J Biological Chem 2004; 279: 22983-91.
37. Legendre P, Westbrook GL. The inhibition of single N-methyl-Daspartate-activated channels by zinc ions on cultured rat neurones. J Physiol 1990; 429: 429-49.
38. Erreger K, Traynelis SF. Zinc inhibition of rat NR1/NR2A Nmethyl-D-aspartate receptors. J Physiol 2008; 586: 763-78.
39. Izumi Y, Auberson YP, Zorumski CF. Zinc modulates bidirectional hippocampal plasticity by effects on NMDA receptors. J Neurosci 2006; 26: 7181-8.
40. Vogt K, Mellor J, Tong G, Nicoll R. The actions of synaptically released zinc at hippocampal mossy fiber synapses. Neuron 2000; 26: 187-96.
41. Sindreu C, Palmiter RD, Storm DR. Zinc transporter ZnT-3 regulates presynaptic Erk1/2 signaling and hippocampus-dependent memory. Proc Natl Acad Sci USA 2011; 108: 3366-70.
42. Hwang JJ, Park MH, Choi SY, Koh JY. Activation of the Trk signaling pathway by extracellular zinc. Role of metalloproteinases. J Biol Chem 2005; 280: 11995-2001.
43. Huang YZ, Pan E, Xiong ZQ, McNamara JO. Zinc-mediated transactivation of TrkB potentiates the hippocampal mossy fiber-CA3 pyramid synapse. Neuron 2008; 57: 546-58.
44. Grabrucker AM, Knight MJ, Proepper C, et al. Concerted action of zinc and ProSAP/Shank in synaptogenesis and synapse maturation. EMBO Journal 2011; 30: 569-81.
45. Takeda A, Minami A, Seki Y, Oku N. Differential effects of zinc on glutamatergic and GABAergic neurotransmitter systems in the hippocampus. J Neurosci Res 2004; 75: 225-9.
46. Erreger K, Traynelis SF. Zinc inhibition of rat NR1/NR2A Nmethyl-D-aspartate receptors. J Physiol 2008; 586: 763-78.
47. Paoletti P, Ascher P, Neyton J. High-affinity zinc inhibition of NMDA NR1-NR2A receptors. J Neurosci 1997; 17: 5711-25.
48. Sensi SL, Paoletti P, Bush AI, Sekler I. Zinc in the physiology and pathology of the CNS. Nature reviews. Neuroscience 2009; 10: 780-91.
49. Wei G, Hough CJ, Li Y, Sarvey JM. Characterization of extracellular accumulation of Zn2+ during ischemia and reperfusion of hippocampus slices in rat. Neuroscience 2004; 125: 867-77.
50. Suh SW, Chen JW, Motamedi M, et al. Evidence that synapticallyreleased zinc contributes to neuronal injury after traumatic brain injury. Brain Res 2000; 852: 268-73.
51. Sensi SL, Yin HZ, Carriedo SG, Rao SS, Weiss JH. Preferential Zn2+ influx through Ca2+-permeable AMPA/kainate channels triggers prolonged mitochondrial superoxide production. Proc Natl Acad Sci USA 1999; 96: 2414-9.
52. Cole TB, Robbins CA, Wenzel HJ, Schwartzkroin PA, Palmiter RD. Seizures and neuronal damage in mice lacking vesicular zinc. Epilepsy Res 2000; 39: 153-69.
53. Qian J, Xu K, Yoo J, et al. Knockout of Zn transporters Zip-1 and Zip-3 attenuates seizure-induced CA1 neurodegeneration. The J neuroscience: the official J the Society for Neuroscience 2011; 31: 97-104.
54. Elsas SM, Hazany S, Gregory WL, Mody I. Hippocampal zinc infusion delays the development of afterdischarges and seizures in a kindling model of epilepsy. Epilepsia 2009; 50: 870-9.
55. Lavoie N, Peralta MR, 3rd, Chiasson M, et al. Extracellular chelation of zinc does not affect hippocampal excitability and seizure-induced cell death in rats. J Physiol 2007; 578: 275-89.
56. Dominguez MI, Blasco-Ibanez JM, Crespo C, et al. Neural overexcitation and implication of NMDA and AMPA receptors in a mouse model of temporal lobe epilepsy implying zinc chelation. Epilepsia 2006; 47: 887-99.
57. Wilson IA, Ikonen S, Gallagher M, Eichenbaum H, Tanila H. Ageassociated alterations of hippocampal place cells are subregion specific. The J neuroscience: the official J Soci Neurosci 2005; 25: 6877-86.
58. Koh MT, Haberman RP, Foti S, McCown TJ, Gallagher M. Treatment strategies targeting excess hippocampal activity benefit aged rats with cognitive impairment. Neuropsychopharmacology: official Pub Am College Neuropsychopharmacol 2010; 35: 1016-25.
59. Celone KA, Calhoun VD, Dickerson BC, et al. Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. The J neuroscience: the official J Soc Neurosci 2006; 26: 10222-31.
60. Dickerson BC, Salat DH, Greve DN, et al. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology 2005; 65: 404-11.
61. Cohen AD, Price JC, Weissfeld LA, et al. Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve. The J neuroscience: the official J Soc Neurosci 2009; 29: 14770-8.
62. Miller SL, Fenstermacher E, Bates J, et al. Hippocampal activation in adults with mild cognitive impairment predicts subsequent cognitive decline. J Neurol, Neurosurg, Psychiatry 2008; 79: 630-5.
63. O'Brien JL, O'Keefe KM, LaViolette PS, et al. Longitudinal fMRI in elderly reveals loss of hippocampal activation with clinical decline. Neurology 2010; 74: 1969-76.
64. Landfield PW, Baskin RK, Pitler TA. Brain aging correlates: retardation by hormonal-pharmacological treatments. Science 1981; 214: 581-4.
65. Issa AM, Rowe W, Gauthier S, Meaney MJ. Hypothalamicpituitary-adrenal activity in aged, cognitively impaired and cognitively unimpaired rats. The J neuroscience: the official J Soc Neurosci 1990; 10: 3247-54.
66. Rapp PR, Gallagher M. Preserved neuron number in the hippocampus of aged rats with spatial learning deficits. Proc Natl Acad SciUSA 1996; 93: 9926-30.
67. Grossi C, Francese S, Casini A, et al. Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease. J Alzheimer's disease: JAD 2009; 17: 423-40.
68. Adlard PA, Cherny RA, Finkelstein DI, et al. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 2008; 59: 43-55.
69. Cherny RA, Atwood CS, Xilinas ME, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001; 30: 665-76.
70. Adlard PA, Bica L, White AR, et al. Metal ionophore treatment restores dendritic spine density and synaptic protein levels in a mouse model of Alzheimer's disease. PloS one 2011; 6: e17669.
71. Lannfelt L, Blennow K, Zetterberg H, et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2008; 7: 779-86.
72. Crouch PJ, Savva MS, Hung LW, et al. The Alzheimer's therapeutic PBT2 promotes amyloid-beta degradation and GSK3 phosphorylation via a metal chaperone activity. J Neurochem 2011.
73. Amatniek JC, Hauser WA, DelCastillo-Castaneda C, et al. Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia 2006; 47: 867-72.
74. Lozsadi DA, Larner AJ. Prevalence and causes of seizures at the time of diagnosis of probable Alzheimer's disease. Dement Geriatr Cogn Disord 2006; 22: 121-4.
75. Hesdorffer DC, Hauser WA, Annegers JF, Kokmen E, Rocca WA. Dementia and adult-onset unprovoked seizures. Neurology 1996; 46: 727-30.
76. Palop JJ, Chin J, Roberson ED, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 2007; 55: 697-711.
77. Minkeviciene R, Rheims S, Dobszay MB, et al. Amyloid betainduced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci 2009; 29: 3453-62.
78. Hunter JM, Cirrito JR, Restivo JL, et al. Emergence of a seizure phenotype in aged apolipoprotein epsilon 4 targeted replacement mice. Brain Res 2012; 1467: 120-32.
79. Sanchez PE, Zhu L, Verret L, et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Nat Acad Sci USA 2012; 109: E2895-903.
80. Ziyatdinova S, Gurevicius K, Kutchiashvili N, et al. Spontaneous epileptiform discharges in a mouse model of Alzheimer's disease are suppressed by antiepileptic drugs that block sodium channels. Epilepsy Res 2011; 94: 75-85.
81. Bakker A, Krauss GL, Albert MS, et al. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron 2012; 74: 467-74.
82. Bloomenthal AB, Goldwater E, Pritchett DB, Harrison NL. Biphasic modulation of the strychnine-sensitive glycine receptor by Zn2+. Mol Pharmacol 1994; 46: 1156-9.